EC
STRO icon

EntryPoint Capital’s Sutro Biopharma STRO Stock Holding History

EntryPoint Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,099
Closed -$142K – 951
2024
Q3 		$142K Buy
+4,099
New +$161K 0.08% 522
2024
Q2 		– Sell
-6,968
Closed -$394K – 1585
2024
Q1 		$394K Buy
+6,968
New +$308K 0.35% 5

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

EntryPoint Capital's STRO Position: Q4 2024 in Review

EntryPoint Capital sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 4,099 shares — an estimated $142K sold.

EntryPoint Capital first reported a position in STRO in Q1 2024 and held it in 2 quarters. The position peaked at $394K in Q1 2024. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • EntryPoint Capital reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 4,099 Sutro Biopharma shares in Q4 2024, an estimated $142K.
  • EntryPoint Capital first reported a position in Sutro Biopharma in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's Sutro Biopharma position peaked at $394K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.